Edition:
United States

Abbott Laboratories (ABT)

ABT on New York Consolidated

44.69USD
17 Feb 2017
Change (% chg)

$0.49 (+1.11%)
Prev Close
$44.20
Open
$44.17
Day's High
$44.70
Day's Low
$44.09
Volume
9,632,008
Avg. Vol
9,159,244
52-wk High
$45.79
52-wk Low
$36.76

ABT

Chart for ABT

About

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment... (more)

Overall

Beta: 1.43
Market Cap(Mil.): $77,143.88
Shares Outstanding(Mil.): 1,726.20
Dividend: 0.26
Yield (%): 2.37

Financials

  ABT Industry Sector
P/E (TTM): 62.38 28.47 29.39
EPS (TTM): 0.72 -- --
ROI: -- 13.57 13.06
ROE: -- 14.45 14.19

BRIEF-Abbott Laboratories says board of directors shall consist of 12 persons from 11

* Abbott Laboratories-on Feb 16, amended by-laws to provide that co's board of directors shall consist of 12 persons, effective as of February 16, 2017

Feb 17 2017

BRIEF-ABBOTT SETS QUARTERLY DIVIDEND OF $0.265 PER SHARE

* SETS QUARTERLY DIVIDEND OF $0.265 PER SHARE Source text for Eikon: Further company coverage:

Feb 17 2017

Abbott Laboratories may see boost from St. Jude's acquisition: Barron's

NEW YORK Abbott Laboratories is likely to see its shares rise again after trading range-bound for nearly a year on the back of its $25 billion acquisition of medical device-maker St. Jude Medical, Barron's said on Sunday.

Feb 12 2017

BRIEF-FDA grants Abbott first commercial authorization for molecular test to detect zika virus using whole blood

* U.S. FDA grants Abbott the first commercial authorization for a molecular test to detect zika virus using whole blood

Feb 02 2017

BRIEF-Abbott announces U.S. approval for its Assurity Mri pacemaker

* Abbott announces U.S. approval for its Assurity Mri pacemaker, the world's smallest, longest-lasting wireless mri-compatible pacemaker Source text for Eikon: Further company coverage:

Feb 01 2017

Abbott pauses on deals, to focus on St. Jude integration

Abbott Laboratories said it planned to focus on slashing its debt and integrating its $25 billion acquisition of St. Jude Medical in 2017, in a break from the hectic pace of dealmaking last year

Jan 25 2017

UPDATE 3-Abbott pauses on deals, to focus on St. Jude integration

* Shares fall as much as 2.6 pct (Adds conference call details, analyst comment; updates shares)

Jan 25 2017

EU mergers and takeovers (Jan 25)

BRUSSELS, Jan 25 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

Jan 25 2017

BRIEF-European Commission clears Abbott acquisition of Alere

* Alere inc - "We remain highly confident that merger will close according to terms of agreement" with Abbott Source text for Eikon: Further company coverage:

Jan 25 2017

EU clears Abbott acquisition of Alere subject to divestments

BRUSSELS European Union antitrust regulators cleared Abbott Laboratories' proposed $5.8 billion acquisition of diagnostic test maker Alere on Wednesday, subject to the divestment of some of Alere's operations.

Jan 25 2017

More From Around the Web

Competitors

Earnings vs. Estimates